Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | GMNN | O75496 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | THPO | P40225 | 1/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2451575 | 0.96 | ALDH1A1 (0.41) | ALDH1A1MAPTGMNNLMNACYP2D6 | |
| SCHEMBL2448392 | 0.90 | ALDH1A1 (0.43) | ALDH1A1MAPTPARP1PARP2CHRM1 | |
| SCHEMBL2447573 | 0.87 | MAPT (0.45) | ALDH1A1MAPTLMNACYP2D6SMN1; SMN2 | |
| SCHEMBL14833991 | 0.78 | HDAC6 (0.62) | ALDH1A1MAPTGMNNLMNACYP2D6 | |
| SCHEMBL2721453 | 0.77 | MAPT (0.46) | ALDH1A1MAPTLMNACYP2D6SMN1; SMN2 | |
| SCHEMBL15359822 | 0.76 | HDAC6 (0.57) | ALDH1A1MAPTGMNNLMNACYP2D6 | |
| SCHEMBL15436004 | 0.74 | ALDH1A1 (0.44) | ALDH1A1MAPTLMNATSHRPARP1 | |
| SCHEMBL16054059 | 0.73 | ALDH1A1 (0.45) | ALDH1A1MAPTSMN1; SMN2PARP1PARP2 | |
| SCHEMBL1920689 | 0.70 | ALDH1A1 (0.50) | ALDH1A1MAPTGMNNLMNACYP2D6 | |
| SCHEMBL2446340 | 0.70 | SMN1; SMN2 (0.41) | ALDH1A1MAPTLMNASMN1; SMN2PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020117257-A1 | COMBINATION THERAPY OF DIFFUSE LARGE B-CELL LYMPHOMA COMPRISING AN ANTI-CD79B IMMUNOCONJUGATES, AN ALKYLATING AGENT AND AN ANTI-CD20 ANTIBODY | GENENTECH, INC. (US) | 2020-06-11 | — | — | WO | claimed |
| EP-3262071-A1 | METHOD OF USING ANTI-CD79b IMMUNOCONJUGATES | F. Hoffmann-La Roche AG (CH) | 2018-01-03 | — | — | EP | claimed |
| WO-2016049214-A1 | METHOD OF USING ANTI-CD79b IMMUNOCONJUGATES | GENENTECH, INC. (US) | 2016-03-31 | — | — | WO | claimed |
| WO-2025085781-A1 | COMBINATIONS OF IL15/IL15R ALPHA HETERODIMERIC FC-FUSION PROTEINS AND HER2XCD3 BISPECIFIC ANTIBODIES FOR THE TREATMENT OF HER2-POSITIVE CANCERS | GENENTECH, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| EP-4441085-A2 | HIGH SELECTIVE CD229 ANTIGEN BINDING DOMAINS AND METHODS OF USE | University of Utah Research Foundation (US) | 2024-10-09 | — | — | EP | disclosed |
| WO-2024102332-A1 | VACCINE COMPOSITIONS COMPRISING A NEOANTIGEN OF KRAS | HIMV LLC (US) | 2024-05-16 | — | — | WO | disclosed |
| WO-2024091826-A1 | LYOPHILIZED BENDAMUSTINE-CYCLODEXTRIN COMPOSITION | SOFTKEMO PHARMA INC. (CA) | 2024-05-02 | — | — | WO | disclosed |
| EP-4243857-A1 | COMBINATION THERAPIES WITH CHIMERIC ANTIGEN RECEPTOR (CAR)-EXPRESSING CELLS | Novartis AG (CH) | 2023-09-20 | — | — | EP | disclosed |
| WO-2023102201-A2 | HIGH SELECTIVE CD229 ANTIGEN BINDING DOMAINS AND METHODS OF USE | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023044483-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HER2 POSITIVE CANCER | VOYAGER THERAPEUTICS, INC. (US) | 2023-03-23 | — | — | WO | disclosed |
| WO-2022104061-A1 | COMBINATION THERAPIES WITH CHIMERIC ANTIGEN RECEPTOR (CAR)-EXPRESSING CELLS | NOVARTIS AG (CH) | 2022-05-19 | — | — | WO | disclosed |
| EP-2595660-A2 | BENDAMUSTINE ANIONIC-CATIOINIC CYCLOPOLYSACCHARIDE COMPOSITIONS | Supratek Pharma, Inc. (CA) | 2013-05-29 | — | — | EP | disclosed |
| EP-2575785-A1 | ORAL DOSAGE FORMS OF BENDAMUSTINE AND THERAPEUTIC USE THEREOF | Astellas Deutschland GmbH (DE) | 2013-04-10 | — | — | EP | disclosed |
| WO-2012174327-A1 | COMBINATION THERAPIES FOR TREATING HEMATOLOGIC MALIGNANCIES USING PYRIDOPYRIMIDINONE INHIBITORS OF PI3K/MTOR WITH BENDAMUSTINE AND/OR RITUXIMAB | EXELIXIS, INC. (US) | 2012-12-20 | — | — | WO | disclosed |
| WO-2012127277-A2 | BENDAMUSTINE ANIONIC-CATIOINIC CYCLOPOLYSACCHARIDE COMPOSITIONS | SUPRATEK PHARMA, INC. (CA) | 2012-09-27 | — | — | WO | disclosed |
| WO-2011103150-A2 | LYOPHILIZED PREPARATIONS OF BENDAMUSTINE | CEPHALON, INC. (US) | 2011-08-25 | — | — | WO | disclosed |
| EP-2326306-A1 | LIQUID FORMULATIONS OF BENDAMUSTINE | Cephalon, Inc. (US) | 2011-06-01 | — | — | EP | disclosed |
| WO-2010063493-A1 | ORAL DOSAGE FORMS OF BENDAMUSTINE | ASTELLAS DEUTSCHLAND GMBH (DE) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010063476-A2 | SOLID DOSAGE FORMS OF BENDAMUSTINE | ASTELLAS DEUTSCHLAND GMBH (DE) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010036702-A1 | LIQUID FORMULATIONS OF BENDAMUSTINE | CEPHALON, INC. (US) | 2010-04-01 | — | — | WO | disclosed |